Kazia Broadens Paxalisib Reach into Colorectal and HR+ Breast Cancers with Fresh Preclinical Data
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (2.8× avg).
Summary
Kazia reported preclinical data supporting paxalisib in MSS/pMMR colorectal cancer and HR+/HER2- breast cancer, with plans to launch a Phase 2 colorectal trial and expand its TNBC trial into HR+ breast cancer.
Key Events · Product Development and Regulatory · KZIA
-
Paxalisib Shows Preclinical Activity in Colorectal Cancer
In MSS/pMMR colorectal cancer models, paxalisib reduced tumor burden by 52% (p=0.035); adding pembrolizumab further reduced tumor volume by an additional 50% (p=0.022).
-
Phase 2 Colorectal Trial Planned
A five-arm Phase 2 trial is planned in pre-treated MSS/pMMR metastatic colorectal cancer, with enrollment expected to begin Q1 2027 and full enrollment by end of 2027.
-
TNBC Trial Expands into HR+/HER2- Breast Cancer
A three-arm expansion will evaluate paxalisib plus fulvestrant with palbociclib versus standard of care; the first patient is expected by year-end 2026, with full enrollment by end of 2027.
-
New Patent Filings Strengthen IP
Provisional patent applications have been filed covering paxalisib use in colorectal cancer and HR+ breast cancer, supported by preclinical findings and biomarker data.
Analysis · KZIA · Life Sciences
Preclinical results show paxalisib cut tumor burden by 52% in MSS/pMMR colorectal cancer and boosted immunotherapy response by an additional 50%, laying the groundwork for a planned Phase 2 trial. The company is also extending its ongoing TNBC study into HR+/HER2- breast cancer, with the first patient expected by year-end 2026. These represent new indications for the lead asset, supported by new patent filings and a CEO statement that recent financing will fund the HR+ program through completion. While the data are preclinical and clinical validation is still pending, the expansion across two large cancer populations is a meaningful pipeline development.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.9% of the 1728 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.06%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZIA was trading at $12.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.3M. The 52-week trading range was $4.86 to $17.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.